Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth Aldape

Showing results (231-240 of 345) with videos related to

Pageof 35
Sort By:
Journal of Neuropathology and Experimental Neurology|September 22, 2018
A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human GliomaJennifer W Koehler, Andrew D Miller, C Ryan Miller, et al.
Acta Neuropathologica|January 31, 2020
cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomasDaniel J Brat, Kenneth Aldape, Howard Colman, et al.
The Lancet. Digital Health|June 5, 2026
Deep learning for H&E-based meningioma molecular classification and outcome prediction: a retrospective cohort studyAlexander P Landry, Farshad Nassiri, Leeor S Yefet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastomaChristopher E Pelloski, Karla V Ballman, Alfred F Furth, et al.
Neuro-Oncology|October 27, 2012
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02Eudocia Q Lee, John Kuhn, Kathleen R Lamborn, et al.
Neuro-Oncology|May 30, 2019
Polysomy is associated with poor outcome in 1p/19q codeleted oligodendroglial tumorsHui Chen, Cheddhi Thomas, Felipe Andres Munoz, et al.
Acta Neuropathologica|April 24, 2023
Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomasJustin Z Wang, Vikas Patil, Jeff Liu, et al.
Neuro-Oncology|January 17, 2019
Advances in multidisciplinary therapy for meningiomasPriscilla K Brastianos, Evanthia Galanis, Nicholas Butowski, et al.
Neuro-Oncology Advances|November 25, 2020
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02Huanwen Chen, John Kuhn, Kathleen R Lamborn, et al.
Acta Neuropathologica|May 12, 2023
Correction: Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomasJustin Z Wang, Vikas Patil, Jeff Liu, et al.
Pageof 35

Showing results (231-240 of 345) with videos related to

Sort By:
Pageof 35
Journal of Neuropathology and Experimental Neurology|September 22, 2018
A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human GliomaJennifer W Koehler, Andrew D Miller, C Ryan Miller, et al.
Acta Neuropathologica|January 31, 2020
cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomasDaniel J Brat, Kenneth Aldape, Howard Colman, et al.
The Lancet. Digital Health|June 5, 2026
Deep learning for H&E-based meningioma molecular classification and outcome prediction: a retrospective cohort studyAlexander P Landry, Farshad Nassiri, Leeor S Yefet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastomaChristopher E Pelloski, Karla V Ballman, Alfred F Furth, et al.
Neuro-Oncology|October 27, 2012
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02Eudocia Q Lee, John Kuhn, Kathleen R Lamborn, et al.
Neuro-Oncology|May 30, 2019
Polysomy is associated with poor outcome in 1p/19q codeleted oligodendroglial tumorsHui Chen, Cheddhi Thomas, Felipe Andres Munoz, et al.
Acta Neuropathologica|April 24, 2023
Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomasJustin Z Wang, Vikas Patil, Jeff Liu, et al.
Neuro-Oncology|January 17, 2019
Advances in multidisciplinary therapy for meningiomasPriscilla K Brastianos, Evanthia Galanis, Nicholas Butowski, et al.
Neuro-Oncology Advances|November 25, 2020
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02Huanwen Chen, John Kuhn, Kathleen R Lamborn, et al.
Acta Neuropathologica|May 12, 2023
Correction: Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomasJustin Z Wang, Vikas Patil, Jeff Liu, et al.
Pageof 35